Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04141 (
granulocyte-macrophage colony-stimulating factor
)
6,790
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Vascular endothelial growth factor
(
VEGF
) is a multifunctional cytokine involved in angiogenesis, inflammation, and wound healing. It is secreted by a variety of tumor cell lines, including hematopoietic lines. Therefore, we investigated expression of
VEGF
and its receptors on fresh leukemic blasts.
VEGF
-specific transcripts were detected by polymerase chain reaction (PCR) in 20 of 28 patients with de novo acute myeloid leukemia (AML) and in 3 of 5 patients with secondary AML. Using immunocytochemistry, we found
VEGF
protein in 2 leukemic cell lines and in 8 AML patients, in concordance with PCR results. Supernatants of fresh leukemic cells from 24 AML patients contained significantly more
VEGF
than supernatants from bone marrow cells of 9 normal donors or of CD34-enriched cells from 3 normal volunteer donors as determined by an enzyme-linked immunosorbent assay.
VEGF
possesses two high-affinity receptors, KDR and FLT1. Using a sensitive nested PCR assay, we detected expression of FLT1 in 10 of 20 patients with de novo AML and 3 of 5 patients with secondary AML. KDR was expressed in 4 of 22 patients with de novo AML and 1 of 4 with secondary AML. To study possible paracrine growth stimulation of AML blasts, endothelial cells from human umbilical cords were incubated with increasing concentrations of
VEGF
. A dose-dependent increase of
granulocyte-macrophage colony-stimulating factor
secretion from endothelial cells was identified.
...
PMID:Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. 905 6
Vascular endothelial growth factor
(
VEGF
) is a pleiotropic polypeptide that mediates endothelial-cell-specific responses such as induction of proliferation and vascular leakage. We examined the expression of
VEGF
messenger RNA (mRNA) and protein by human eosinophils in response to
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) and interleukin-5 (IL-5). Immunoreactive
VEGF
protein was detected in freshly isolated eosinophils by immunocytochemistry. Eosinophils spontaneously released
VEGF
protein in culture medium, and this release was upregulated by
GM-CSF
or IL-5. Freshly isolated eosinophils constitutively expressed VEGF mRNA. Although incubation of eosinophils in culture medium reduced steady-state VEGF mRNA levels, eosinophil VEGF mRNA levels were enhanced by
GM-CSF
and IL-5, and this enhancement was blocked by the transcription inhibitor actinomycin D. Analysis of alternatively spliced mRNA species revealed that eosinophils contained transcripts mainly encoding for the 121- and 165-amino-acid forms of
VEGF
. VEGF mRNA expression and
VEGF
release in cytokine-stimulated eosinophils were significantly reduced by treatment with a glucocorticosteroid, a protein-tyrosine kinase inhibitor, or a protein kinase C inhibitor. Cytokine-activated eosinophils may be an important source of a vascular permeability factor, namely
VEGF
, thus contributing to tissue edema formation at sites of allergic inflammation.
...
PMID:Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. 922 11
Vascular endothelial growth factor
(
VEGF
) production was analysed in megakaryocytic cell lines and CD34+ haematopoietic progenitors following treatment with thrombopoietin (TPO). In CMK cells TPO caused a time- and dose-dependent increase in the levels of
VEGF
released into the medium. A similar effect was observed in UT-7/mpl cells transfected with the TPO receptor c-Mpl, but not in parental UT-7 cells. In CD34+ haematopoietic progenitor cell cultures TPO stimulated VEGF mRNA expression and
VEGF
protein release. Production of
VEGF
in CD34+ cultures increased with TPO-induced megakaryocytic differentiation, but not with erythroid or myelomonocytic differentiation induced respectively by erythropoietin and
granulocyte-macrophage colony-stimulating factor
. These results demonstrate that TPO stimulates
VEGF
release in c-Mpl-expressing cells and suggest that this process is an integral feature of the megakaryocytic differentiation programme.
...
PMID:Thrombopoietin stimulates VEGF release from c-Mpl-expressing cell lines and haematopoietic progenitors. 950 32
Vascular endothelial growth factor
(
VEGF
) is a key regulator of vasculo- and angiogenesis. Earlier studies demonstrated a permeability-increasing effect of
VEGF
in skin tests, leading to its other name, vascular permeability factor. We wondered whether
VEGF
-induced hyperpermeability was a direct effect of
VEGF
on endothelial cells and studied the permeability of human and porcine endothelial cell monolayers in a well-characterized in vitro system.
VEGF
increased the hydraulic conductivity up to 20-fold and simultaneously decreased the albumin reflection coefficient. This effect occurred after a delay of 150 min, although
VEGF
-induced early endothelial cell activation was verified by enhanced inositol phosphate accumulation within 5 min and increased P-selectin expression within 15 min. Platelet-derived growth factor and
granulocyte-macrophage colony-stimulating factor
, two endothelial cell nonspecific mitogens, also stimulated phosphatidylinositol metabolism and P-selectin expression; however, they had no effect on endothelial permeability. The increase in intracellular cyclic nucleotide levels of human endothelial monolayers abolished
VEGF
-induced endothelial hyperpermeability. In summary,
VEGF
increased endothelial permeability by a direct action on endothelial cells. Based on the pattern of endothelial cell activation by growth factors,
VEGF
appears to be a unique stimulus.
...
PMID:VEGF induces hyperpermeability by a direct action on endothelial cells. 961 82